Fwd: No Benefit from Enhanced Coenzyme Q10 in PD (AAN 2008)

["M.Schild" <mmoo@xxxxxxxxxxxxxxxx>]

Phase II study of the mitochondrial antioxidant MitoQ for Parkinson's disease
B Snow, F Booth, M Lockhart, C Frampton, RAJ Smith, MP Murphy, K Taylor
IN6-1.009, A483

A chemically modified form of coenzyme Q10 with 1000 times the protective 
power against oxidative stress does not alter the course of Parkinson's 
disease, according to this report.

Mitoquinone is an CoQ10 derivative with a highly lipophilic tail, designed to 
pass more easily into mitochondria. In animal models, it is 1000 times as 
protective against oxidative stress as CoQ10 itself. 

One hundred thirty PD patients with mean UPDRS total score of 25.5 were 
randomized to placebo, 40 mg/day, or 80 mg/day mitoquinone. After 12 months, 
there was no difference among the groups on total UPDRS, UPDRS subscores, 
Schwab and England scale, Mini-Mental State Exam, time tapping, or time to 
requirement for antiparkinson medication.

The authors conclude, "The clear lack of effect on the progression of PD shown 
in this trial must be considered when considering the hypothesis that 
mitochondrial oxidative stress plays a central role in the progression of 
PD."




This message was sent by WE MOVE.ORG using ReachMail.

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:listserv@xxxxxxxxxxxxxxxxxxxx
In the body of the message put: signoff parkinsn